Glenmark Pharmaceuticals Ltd (NSE:GLENMARK)
₹ 1194.15 -15.7 (-1.3%) Market Cap: 336.71 Bil Enterprise Value: 330.69 Bil PE Ratio: 0 PB Ratio: 4.29 GF Score: 83/100

Full Year 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript

May 31, 2021 / 03:00AM GMT
Release Date Price: ₹592.5 (-2.49%)
Operator

Ladies and gentlemen, good day, and welcome to Q4 FY '21 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Ravi Agrawal. Thank you, and over to you, sir.

Ravi Agrawal
Glenmark Pharmaceuticals Limited - IR Officer

Yes. Thank you, moderator. Good morning, everyone, and a warm welcome to the Q4 FY '21 Results Conference Call of Glenmark Pharmaceuticals Limited.

Before we start the call, a review of the operations of the company. For the fourth quarter of FY 2021, Glenmark's consolidated revenue was at INR 28,599 million, recording an increase of 3.3% year-on-year. For the year ending March 31, 2021, Glenmark's consolidated revenue was at INR 109,439 million, recording an increase of 2.8% year-on-year.

Our corporate announcement. Glenmark Life Sciences Limited has filed a DRHP with the Securities and Exchange Board of India for a proposed IPO comprising a fresh issue of up to INR 11,600 million and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot